Skin and Joints Podcast cover art

Skin and Joints Podcast

Skin and Joints Podcast

By: Mimi Tran Aaron Sihota Danny Mansour Ashley Yip Julia Tan Touraj Khosravi Anastasiya Muntyanu
Listen for free

This Season's Biggest Deal | £0.99/mo for 3 months + £10 Audible bonus

£5.99/mo after 3 months - terms apply. Cancel monthly
A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.2026 Skin and Joints Podcast Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 2)

    Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 2)
    Oct 20 2026
    🇨🇦🇺🇸 Cross-Border Talk: High Fives, Higher Standards — Rethinking the Treatment Finish Line (Part 2 of 2)🎰 What happens in Vegas doesn't always stay in Vegas—especially when it could change how we treat patients! 🇨🇦 Team Canada and 🇺🇸 Team USA are back for Round 2!Live from Fall Clinical 2026 in Las Vegas, Canadian dermatologist Dr. Andrei Metelitsa and American dermatologist Dr. Christopher Bunick return to the Skin and Joints Podcast for Part 2 of our Cross-Border Talk series.This time we're raising the stakes—and the standard of care.🤔 What good is a better eczema score if your patient still can't sleep, work, or even shake someone's hand?Our experts go beyond skin clearance to explore why minimal disease activity, patient-reported outcomes, and real-world functionality should be central to how we define treatment success in atopic dermatitis and chronic hand eczema.🔬 Diving deeper into the AD Hand study, they unpack emerging tralokinumab data showing meaningful improvements in quality of life and hand function. But how quickly should patients expect results? And when is an improving partial response good enough—or a signal to rethink the treatment plan?🩺 Then comes the ultimate cross-border real world clinical challenge: a 38 year old nurse whose painful hand eczema threatens her ability to work, despite optimized topical therapy. Would Team Canada and Team USA approach treatment differently? When is it time to escalate therapy—and what happens once patients finally achieve clear skin?💡 From biologics and JAK inhibitors to shared decision-making, irritant avoidance, and the intriguing question of what happens after patients achieve clear skin, this conversation serves up practical clinical pearls—with a few laughs along the way.🙌 Two countries. One treatment goal. Helping patients high-five with confidence again! 🎯 Learning ObjectivesFollowing this episode, healthcare professionals should be able to:Redefine meaningful treatment success: Discuss the clinical value of minimal disease activity and more stringent treat-to-target goals, integrating skin clearance, itch control, and patient-reported outcomes rather than relying solely on conventional disease severity scores.Translate clinical trial findings into real-world outcomes: Interpret findings from the AD Hand study examining tralokinumab's impact on Dermatology Life Quality Index (DLQI) and Hand Eczema Impact Scale (HEIS) outcomes, and consider their relevance to daily functioning and quality of life.Set realistic treatment expectations: Evaluate the significance of early responses, continued improvement over time, and partial treatment responses when counselling patients with atopic hand eczema, while recognizing the importance of ongoing skin care and irritant avoidance.Navigate treatment escalation in high-burden disease: Apply a patient-centred approach to clinical decision-making in patients with functionally debilitating atopic hand eczema, including consideration of biologics, JAK inhibitors, occupational factors, concomitant therapies, and differences in treatment availability across Canada and the United States.Look beyond achieving clear skin: Explore emerging considerations for long-term disease control, maintenance strategies, dosing flexibility, and potential treatment de-escalation once patients achieve meaningful disease control, while recognizing the limits of current evidence. 🎲 The stakes are high, the clinical pearls are plenty, and the borders are open for debate.Because at the end of the day, successful eczema treatment isn't just about how the skin looks—it's about what patients can finally get back to doing. 🙌#SkinAndJoints #CrossBorderTalk #FallClinical2026 #AtopicDermatitis #ChronicHandEczema #ADHand #JAKs #MinimalDiseaseActivity #PatientReportedOutcomes #Dermatology #TreatToTarget SUPPORTED BY AN IME GRANT FROM LEO Pharma. About Dr. Christopher Bunick MD, PhD.Dermatologist | New Haven, CT, USA BIOGRAPHYDr. Christopher Bunick is an Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine. Clinically, he specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. Dr. Bunick received his B.S. at Vanderbilt University (Nashville, TN), and his M.D. and Ph.D. degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g. the skin disease xeroderma pigmentosum). He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at the Yale University School of Medicine (New Haven, CT). He performs lab research with the goal ...
    Show More Show Less
    24 mins
  • Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 1)

    Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 1)
    Oct 13 2026
    🎰 Cross-Border Talk: High Stakes, Higher Standards — Rethinking Atopic Dermatitis & Chronic Hand Eczema (Part 1 of 2)🇨🇦 Team Canada vs. Team USA. Different borders, shared clinical challenges—and a few (somewhat friendly) disagreements along the way!🎙️ Live from Fall Clinical 2026 in Las Vegas, the Skin and Joints Podcast brings back its popular Cross-Border Talk segment, featuring Canadian dermatologist Dr. Andrei Metelitsa and American dermatologist Dr. Christopher Bunick.From exchange-rate banter to exchanging clinical pearls, the conversation quickly turns to some big questions in dermatology: Are we intervening early enough? Have we become too comfortable with corticosteroids? And are we setting the bar high enough for treatment success?🔥 In Part 1 of this two-part conversation, our experts unpack their biggest takeaways from Fall Clinical, challenge conventional thinking around JAK inhibitor safety, and explore why corticosteroid stewardship and newer non-steroidal therapies could help break the cycle of therapeutic inertia in chronic hand eczema.🔬 The discussion gets beneath the surface—literally—as they examine emerging pediatric TRAPEZE-1 data exploring IL-13 inhibition and skin barrier biomarkers, alongside AD Hand study findings that challenge how we define disease severity and meaningful treatment outcomes.💡 And perhaps the biggest question: If a patient has limited skin involvement but can't sleep, work, or function because of their eczema, can we really call their disease mild?Two countries. Two dermatologists. One candid conversation about raising the standard of care.Because when it comes to better dermatology care, some boundaries are worth crossing. 🌎🎯 Learning ObjectivesAfter listening to this episode, healthcare professionals should be able to:Rethink early intervention: Discuss the clinical rationale for earlier use of advanced therapies in inflammatory skin diseases and evaluate evolving evidence surrounding JAK inhibitor safety in atopic dermatitis.Challenge the corticosteroid status quo: Recognize therapeutic inertia in chronic hand eczema and explore how steroid stewardship, non-steroidal topical therapies, and appropriate treatment escalation can improve long-term management.Look beyond visible skin clearance: Interpret exploratory TRAPEZE-1 pediatric findings on skin barrier biomarkers following IL-13 inhibition, while distinguishing potential barrier restoration from established disease modification.Redefine disease burden: Examine how atopic hand eczema can profoundly affect itch, pain, sleep, daily functioning, and quality of life despite relatively limited body surface area involvement.Raise the treatment bar: Discuss minimal disease activity and the value of integrating clinician-assessed outcomes with patient-reported outcomes when establishing meaningful treatment goals.🇨🇦 🇺🇸 Two perspectives. Plenty of clinical pearls. No passport required.#SkinAndJoints #CrossBorderTalk #FallClinical2026 #AtopicDermatitis #ChronicHandEczema #SteroidStewardship #SkinBarrier #JAKInhibitors #Dermatology SUPPORTED BY AN IME GRANT FROM LEO Pharma. About Dr. Christopher Bunick MD, PhD.Dermatologist | New Haven, CT, USA BIOGRAPHYDr. Christopher Bunick is an Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine. Clinically, he specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. Dr. Bunick received his B.S. at Vanderbilt University (Nashville, TN), and his M.D. and Ph.D. degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g. the skin disease xeroderma pigmentosum). He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at the Yale University School of Medicine (New Haven, CT). He performs lab research with the goal of better understanding the structure-function relationship of proteins involved in normal and diseased skin and dermatologic therapeutics. His work emphasizes translation of biochemical and structural research findings into clinically meaningful and practice-changing discoveries. His work to date has advanced the field’s understanding of: (i) the molecular mechanisms of the human skin barrier; (ii) assembly mechanisms of intermediate filaments, like keratin and vimentin, leading to patents for new cytoskeleton-targeted therapeutics; (iii) the biochemical basis for antibiotic activity and resistance in Cutibacterium acnes and acne vulgaris; (iv) the structure-function relationships of anti-IL23 psoriasis biologics and how that impacts clinical efficacy; (v) the ...
    Show More Show Less
    32 mins
  • Beyond Skin Deep & Gut Feelings: Mastering IBD and Psoriatic Care PART 3

    Beyond Skin Deep & Gut Feelings: Mastering IBD and Psoriatic Care PART 3
    Jul 28 2026
    Part 3 of 3: Our Practical Playbook When Skin & Gut Don’t Read the Same Treatment PlanWhat happens when the skin is crystal clear…but the Crohn’s disease didn’t get the memo? 👀In the final chapter of our special Derm × GI crossover conversation, our Faculty Dr. Perry Grewal and Dr. Jesse Siffledeen get practical about what happens after the prescription is written.From treat-to-target monitoring and follow-up cadence to the very real influence of insurance requirements, our experts unpack how they decide whether a therapy is truly working—and what to do when different organ systems are telling very different stories.🧩 Great skin, active gut?🧩 Controlled IBD, stubborn psoriasis?🧩 One therapy, two diseases…or occasionally two therapies?The conversation explores how clinicians prioritize competing treatment targets without sacrificing what matters most to the patient, why success may need to be measured beyond a single organ system, and where communication between specialties becomes essential.And perhaps the simplest clinical pearl of the entire series? Ask the questions—and don’t be afraid to pick up the phone.Because when inflammatory disease crosses specialties, the best care probably should too. 🎯 Learning ObjectivesAfter listening to this episode, participants should be able to:Describe practical approaches to monitoring treatment response across dermatologic and gastrointestinal inflammatory diseases, including the role of early clinical follow-up and objective assessment.Evaluate therapeutic options when disease control differs across organ systems, such as controlled psoriasis with active IBD or controlled IBD with persistent skin disease.Discuss the limitations of organ-specific treatment targets and incorporate patient priorities, disease severity, and multisystem outcomes when defining therapeutic success.Recognize how payer and insurance requirements can influence treatment selection, reassessment schedules, access, and consideration of dual therapy.Identify key questions that dermatology and gastroenterology clinicians can ask to recognize disease manifestations outside their own specialty and facilitate timely referral.Apply practical strategies for multidisciplinary co-management, including direct clinician-to-clinician communication and collaborative treatment decision-making,🔥 In This Episode🔬 Treat-to-target: when should you actually reassess?🎯 One patient, two organs: does success require both to be at target?🔄 Great skin, active gut—or vice versa: when do you switch?💊 Dual therapy: useful tool or access nightmare?💰 When insurance starts influencing the clinical calendar🗣️ Why asking about the gut–skin–joint connection matters📞 The underrated power of simply calling your colleague🤝 Why multidisciplinary care needs to move from concept to everyday workflow #SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #TreatToTarget #Biologics #IL23 #InflammatoryDisease #MultidisciplinaryCare #PrecisionMedicine #PatientCentredCare #MedicalEducation #HCPeducation SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson. ABOUT Dr. Parbeer GrewalDermatologist, Edmonton, ABDr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology. Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology. He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services. ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, ABDr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit...
    Show More Show Less
    19 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet